IRADIMED CORP

Listed Company

IRMDCIK 0001325618NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$83.81M

Net Income

$22.48M

Total Assets

$108.78M

Equity

$94.62M

Shares Out

12.78M

Op. Cash Flow

$24.95M

Business

IRADIMED CORP develops, manufactures, markets and distributes MRI compatible medical devices and related accessories, disposables and services for use in the MRI environment. Its main products include the MRidium MRI compatible IV infusion pump system, the 3880 MRI compatible patient vital signs monitoring system, ferromagnetic detection devices, proprietary disposable IV tubing sets, extended warranty agreements and related maintenance services. The company operates as a single reportable segment focused on MRI patient care technologies and product support. It sells primarily to hospitals and acute care facilities through a U.S. direct sales force and independent international distributors.

Summary from filing dated 2025-03-06

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	84	73	66	53	42
Cost of revenue	19	17	15	12	10
Gross profit	64	56	50	41	32
General and administrative	18	16	15	11	10
Sales and marketing	17	16	12	13	11
Research and development	3	3	3	2	2
Total operating expenses	38	34	30	26	22
Income from operations	26	22	20	16	10
Other income, net	2	2	2	553,104	18,605
Income before provision for income taxes	28	24	22	16	10
Provision for income tax expense	6	5	5	3	510,816
Net income	22	19	17	13	9
Basic (in dollars per share)	1.77	1.52	1.36	1.02	0.76
Diluted (in dollars per share)	1.75	1.5	1.35	1.02	0.74
Basic (in shares)	13	13	13	13	12
Diluted (in shares)	13	13	13	13	13

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	51	52	50	58	62
Accounts receivable, net of allowance for credit losses of $191 as of December 31, 2025, and $274 as of December 31, 2024	14	11	12	13	5
Inventory, net	12	10	13	5	4
Prepaid expenses and other current assets	5	2	1	630,960	1
Total current assets	81	75	76	77	76
Property and equipment, net	24	17	9	2	2
Intangible assets, net	3	3	3	2	1
Deferred tax asset, net	94,000	3	2	700,867	765,096
Other assets	239,000	354,000	181,449	648,672	201,325
Total assets	109	98	92	86	83
Accounts payable	2	2	2	2	782,903
Accrued payroll and benefits	3	4	3	3	3
Warranty reserve	144,000	118,000	117,463	94,030	108,880
Deferred revenue	3	2	3	3	3
Other current liabilities	313,000	466,000	250,000	—	146,435
Accrued income taxes	2	—	250,041	—	—
Total current liabilities	10	9	16	9	7
Deferred revenue, non-current	4	3	3	1	2
Operating lease liabilities, non-current	—	2,000	2	2	2
Total liabilities	14	12	21	12	11
Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,781,774 shares issued and outstanding as of December 31, 2025, and 12,709,860 shares issued and outstanding as of December 31, 2024	1,000	1,000	1,265	1,259	1,254
Additional paid-in capital	30	30	28	26	25
Retained earnings	64	57	43	47	47
Total stockholders' equity	95	87	71	74	72
Total liabilities and stockholders' equity	109	98	92	86	83

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net income	22	19	17	13	9
Allowance for credit losses	−84,000	−95,000	208,337	102,767	13,876
Provision for excess and obsolete inventory	47,000	88,000	181,443	55,737	118,217
Depreciation & amortization	1	818,000	765,180	670,673	1
Loss on disposal of property and equipment	37,000	4,000	12,537	−1,741	5,544
Stock-based compensation	3	3	2	1	1
Deferred income taxes, net	3	−698,000	−1	57,097	523,607
Accounts receivable	−3	2	841,911	−8	−575,543
Inventory	−1	3	−7	−1	−393,316
Prepaid income taxes	−3	−786,000	—	—	—
Prepaid expenses and other current assets	−132,000	−320,000	−562,487	305,936	−1
Other assets	−40,000	−17,000	467,223	−398,224	26,557
Accounts payable	−76,000	−862,000	−216,436	1	30,414
Accrued payroll and benefits	−554,000	997,000	−96,787	57,330	1
Other accrued taxes	150,000	60,000	−18,678	−18,396	36,334
Warranty reserve	26,000	1,000	23,433	−14,850	18,826
Deferred revenue	2	−111,000	615,636	530,576	48,062
Other current liabilities	−150,000	−100,000	250,000	−146,435	—
Accrued income taxes	2	−786,051	254,093	3	−829,227
Net cash provided by operating activities	25	26	13	10	11
Purchases of property and equipment	−8	−8	−7	−823,019	−482,325
Capitalized intangible assets	−656,000	−812,000	−566,657	−1	−259,434
Net cash used in investing activities	−8	−9	−8	−1	648,241
Dividends paid	−15	−14	−13	−13	—
Proceeds from exercises of stock options	—	29,000	176,744	146,708	623,242
Taxes paid related to the net share settlement of equity awards	−3	−688,000	−610,348	−293,981	−598,817
Net cash used in financing activities	−18	−14	−14	−13	24,425
Net (decrease) increase in cash and cash equivalents	−1	2	−8	−4	12
Cash paid for income taxes	4	7	5	2	970,000
ROU asset and liability adjustment	—	1	—	—	—
Operating and short-term lease payments recorded within cash flow provided by operating activities	489,000	817,000	675,190	534,469	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro